AstraZeneca Archives - Occasional Digest

15 November 2026 4:40 AM

MONEY

AstraZeneca PLC Non-GAAP EPS of $2.79, revenue of $16.21B beats by $210M; reaffirms FY2026

AstraZeneca PLC press release (AZN): Q3 Non-GAAP EPS of $2.79.
Revenue of $16.21B (+6.7% Y/Y) beats by $210M.
FY2026 Guidance AstraZeneca reconfirms: Total Revenue is expected to increase by a mid-to-high single-digit percentage.
Core EPS is expected to increase

Source link

MONEY

AstraZeneca stomach cancer drug doubles survival in late-stage trial (AZN:NYSE)

Oct 25, 2026 Finance Desk

AstraZeneca company office building — Robert Way/iStock Editorial via Getty Images

AstraZeneca (AZN) said its experimental stomach cancer treatment doubled survival time in a late-stage clinical trial, strengthening prospects for a medicine the British drugmaker estimates could generate as much as $5 billion in annual sales.

The drug, sonesitatug vedotin, also known as

Source link